Klinische Studien | Universitätsklinikum Ulm

Onkologische Studien

A phase I trial of obinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients

Protokoll-Nr.	SAKK 35/15
Sponsor	SAKK - SWISS GROUP FOR CLINICAL CANCER RESEARCH, German Lymphoma Study Group
EudraCT-Nr.	2017-001175-23
Studie der Inneren Medizin 3

A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)

Protokoll-Nr.	20150288
Sponsor	Amgen Inc
EudraCT-Nr.	2016-002190-35
Studie der Inneren Medizin 3

A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination with Pembrolizumab in Adult Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) AMG 103/Blinatumomab MK-3475/Pembrolizumab

Protokoll-Nr.	20150290
Sponsor	Amgen Inc
EudraCT-Nr.	2016-002191-27
Studie der Inneren Medizin 3

A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma

Protokoll-Nr.	MK3475-412
Sponsor	Merck KGaA
EudraCT-Nr.	2016-003934-25
Studie der HNO

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - (KEYNOTE-365)

Protokoll-Nr.	MK3475-365
Sponsor	Merck Sharp & Dohme Corp
EudraCT-Nr.	2016-002312-41
Studie der Urologie

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Protokoll-Nr.	ACE-LY-308
Sponsor	Acerta Pharma
EudraCT-Nr.	2015-005220-26
Studie der Inneren Medizin 3

Neurologische Studien

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension

Protokoll-Nr	BP39529 (PASADENA)
Sponsor	F. Hoffmann-La Roche Ltd
EudraCT-Nr	2017-000087-15

A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction

Protokoll-Nr	CLCZ696B2320
Sponsor	Novartis
EudraCT-Nr	2016-001254-17

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients with Mild Alzheimer’s Disease

Protokoll-Nr	814907-CS1
Sponsor	IONIS
EudraCT-Nr	2016-002713-22

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study Of Crenezumab In Patients With Prodromal To Mild Alzheimer’S Disease

Protokoll-Nr	BN29552
Sponsor	F. Hoffmann-La Roche Ltd
EudraCT-Nr	2015-003034-27

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Protokoll-Nr	221AD302
Sponsor	Biogen MA Inc
EudraCT-Nr	2015‐000967‐15